PIK3CA and breast cancer: Takeshita and coworkers reached a similar conclusion, who explored a group of early and late, metastatic ER+ breast cancer patients and showed that PIK3CA mutations, detected on circulating plasma DNA, were not associated with clinical outcome [303].